Skip to main content
Evidence Snapshot

Cyclin-dependent kinase 4

CHEMBL331 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:34Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL331
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cyclin-dependent kinase 4 as ChEMBL target CHEMBL331, mapped to UniProt P11802. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cyclin-dependent kinase 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL331
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P11802
Cyclin-dependent kinase 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Cyclin-dependent kinase 4 matters

As of 2026-09-13

Cyclin-dependent kinase 4 is reviewed as Cyclin-dependent kinase 4 (UniProt P11802); Cyclin-dependent kinase 4 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 12 approved drugs, 2436 compounds, and 358 assays, with lead potency reaching pChEMBL 10.6.

Disease context
breast cancer

Cyclin-dependent kinase 4 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ABEMACICLIB, ALVOCIDIB, RIBOCICLIB.

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include ABEMACICLIB, ALVOCIDIB, RIBOCICLIB, RIBOCICLIB SUCCINATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 6 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 12 approved drugs, 2436 compounds, and 358 assays for this target. The dominant activity type is IC50. CHEMBL151546 is the current potency anchor at pChEMBL 10.6.

Use CHEMBL151546 as the tractability anchor when discussing potency (pChEMBL 10.6).

Activity source · ChEMBL 36 via Core Engine
12 approved pChEMBL 10.6
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Cyclin-dependent kinase 4 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P11802, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why breast cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2436
Total Compounds
358
Total Assays
12
Approved Drugs
IC50: 1771.0, KI: 117.0, KD: 389.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL151546
 10.6 IC50 —
No preferred name
CHEMBL5841163
 10.2 IC50 —
No preferred name
CHEMBL148580
 10.1 IC50 —
No preferred name
CHEMBL6064669
 10.1 IC50 —
No preferred name
CHEMBL5765852
 10.0 IC50 —

Approved Drugs

Structure Compound First Approval
FEDRATINIB
CHEMBL1287853
 2019
ENCORAFENIB
CHEMBL3301612
 2018
ABEMACICLIB
CHEMBL3301610
 2017
RIBOCICLIB
CHEMBL3545110
 2017
PALBOCICLIB
CHEMBL189963
 2015
NINTEDANIB
CHEMBL502835
 2014
DABRAFENIB
CHEMBL2028663
 2013
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:34Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL331